Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells

JCI Insight

Volumn 1, Issue 21, 2016, Pages

  Boddupalli, Chandra Sekhar ^a   Bar, Noffar ^a   Kadaveru, Krishna ^a   Krauthammer, Michael ^a   Pornputtapong, Natopol ^a   Mai, Zifeng ^a   Ariyan, Stephan ^a   Narayan, Deepak ^a   Kluger, Harriet ^a,b   Deng, Yanhong ^a   Verma, Rakesh ^a   Das, Rituparna ^a   Bacchiocchi, Antonella ^a   Halaban, Ruth ^a   Sznol, Mario ^a,b   Dhodapkar, Madhav V ^a,b   Dhodapkar, Kavita M ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85020142467     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.88955     Document Type: Article

References (49)

1. Bindea G, Mlecnik B, Angell HK, Galon J. The immune landscape of human tumors: Implications for cancer immunotherapy. Oncoimmunology. 2014; 3(1):e27456.
2. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10.
3. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013; 19(5):1021-1034.
4. Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol. 2013; 31:137-161.
5. Schenkel JM, Masopust D. Tissue-resident memory T cells. Immunity. 2014; 41(6):886-897.
6. Sathaliyawala T, et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity. 2013; 38(1):187-197.
7. Djenidi F, et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 2015; 194(7):3475-3486.
8. Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014; 20(2):434-444.
9. Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. Immunol Res. 2012; 53(1-3):41-57.
10. Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implications of tumor heterogeneity. Clin Cancer Res. 2015; 21(6):1258-1266.
11. Sanborn JZ, et al. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci USA. 2015; 112(35):10995-11000.
12. Watanabe R, et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med. 2015; 7(279):279ra39.
13. Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med. 2015; 21(7):688-697.
14. Mackay LK, et al. The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat Immunol. 2013; 14(12):1294-1301.
15. Wakim LM, et al. The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J Immunol. 2012; 189(7):3462-3471.
16. Pasetto A, et al. Tumor- and neoantigen-reactive T-cell receptors can ce identified based on their frequency in fresh tumor. Cancer Immunol Res. 2016; 4(9):734-743.
17. Clark RA. Resident memory T cells in human health and disease. Sci Transl Med. 2015; 7(269):269rv1.
18. Gros A, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014; 124(5):2246-2259.
19. Baitsch L, et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest. 2011; 121(6):2350-2360.
20. Zhang L, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-213.
21. Li YL, Zhao H, Ren XB. Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?. Cancer Biol Med. 2016; 13(2):206-214.
22. Hodi FS, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014; 2(7):632-642.
23. Thome JJ, et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell. 2014; 159(4):814-828.
24. thor Straten P, et al. In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol. 1999; 163(1):443-447.
25. Yazdi AS, et al. Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J Invest Dermatol. 2006; 126(2):393-398.
26. Powles T, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558-562.
27. Romano E, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA. 2015; 112(19):6140-6145.
28. Iijima N, Iwasaki A. T cell memory. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science. 2014; 346(6205):93-98.
29. Malyguine AM, Strobl SL, Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother. 2012; 61(2):239-247.
30. Kluger HM, et al. Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res. 2015; 21(13):3052-3060.
31. Das R, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015; 194(3):950-959.
32. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012; 12(4):269-281.
33. Yu CI, et al. Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-β. Immunity. 2013; 38(4):818-830.
34. Gaide O, et al. Common clonal origin of central and resident memory T cells following skin immunization. Nat Med. 2015; 21(6):647-653.
35. Krauthammer M, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012; 44(9):1006-1014.
36. Khan TN, Mooster JL, Kilgore AM, Osborn JF, Nolz JC. Local antigen in nonlymphoid tissue promotes resident memory CD8+ T cell formation during viral infection. J Exp Med. 2016; 213(6):951-966.
37. Jacquelot N, et al. Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest. 2016; 126(3):921-937.
38. Salerno EP, Olson WC, McSkimming C, Shea S, Slingluff CL. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer. 2014; 134(3):563-574.
39. Boddupalli CS, et al. ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. J Clin Invest. 2016; 126(10):3905-3916.
40. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003; 26(4):332-342.
41. Amir el-AD, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol. 2013; 31(6):545-552.
42. Sehgal K, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015; 125(26):4042-4051.
43. Nair S, et al. Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. Blood. 2015; 125(8):1256-1271.
44. Emerson R, Sherwood A, Desmarais C, Malhotra S, Phippard D, Robins H. Estimating the ratio of CD4+ to CD8+ T cells using high-throughput sequence data. J Immunol Methods. 2013; 391(1-2):14-21.
45. Robins HS, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009; 114(19):4099-4107.
46. DeWitt WS, et al. Dynamics of the cytotoxic T cell response to a model of acute viral infection. J Virol. 2015; 89(8):4517-4526.
47. Tworkoski K, et al. Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res. 2011; 9(6):801-812.
48. Hoof I, et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics. 2009; 61(1):1-13.
49. Nielsen M, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One. 2007; 2(8):e796.